ANI Pharmaceuticals Inc (NASDAQ:ANIP) major shareholder Meridian Venture Partners Ii L sold 61,697 shares of the firm’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $71.64, for a total transaction of $4,419,973.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Meridian Venture Partners Ii L also recently made the following trade(s):

  • On Friday, August 9th, Meridian Venture Partners Ii L sold 19,860 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $71.70, for a total transaction of $1,423,962.00.

NASDAQ:ANIP traded up $0.77 during trading hours on Tuesday, reaching $72.05. The company had a trading volume of 132,967 shares, compared to its average volume of 114,583. The company has a market capitalization of $867.91 million, a price-to-earnings ratio of 15.63 and a beta of 2.17. The stock has a 50-day moving average price of $80.84. ANI Pharmaceuticals Inc has a twelve month low of $36.92 and a twelve month high of $86.96. The company has a current ratio of 1.01, a quick ratio of 0.74 and a debt-to-equity ratio of 0.32.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings data on Wednesday, August 7th. The specialty pharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.26. The firm had revenue of $54.36 million during the quarter, compared to analysts’ expectations of $55.20 million. ANI Pharmaceuticals had a net margin of 8.14% and a return on equity of 29.53%. The business’s revenue was up 15.0% on a year-over-year basis. During the same period last year, the company earned $1.13 earnings per share. As a group, equities analysts predict that ANI Pharmaceuticals Inc will post 5.57 EPS for the current year.

ANIP has been the subject of a number of research reports. Canaccord Genuity restated a “buy” rating and issued a $90.00 price target (up from $80.00) on shares of ANI Pharmaceuticals in a report on Monday, May 13th. Zacks Investment Research cut shares of ANI Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday. ValuEngine cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Cantor Fitzgerald restated a “buy” rating and issued a $89.00 price target on shares of ANI Pharmaceuticals in a report on Thursday, May 9th. Finally, BidaskClub cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock. ANI Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $89.00.

Several hedge funds and other institutional investors have recently modified their holdings of ANIP. Financial Gravity Wealth Inc. acquired a new position in shares of ANI Pharmaceuticals during the first quarter valued at about $54,000. Quantamental Technologies LLC grew its holdings in shares of ANI Pharmaceuticals by 169.4% during the first quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after buying an additional 542 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ANI Pharmaceuticals by 237.9% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 794 shares of the specialty pharmaceutical company’s stock valued at $65,000 after buying an additional 559 shares during the last quarter. Municipal Employees Retirement System of Michigan acquired a new position in shares of ANI Pharmaceuticals during the fourth quarter valued at about $115,000. Finally, BNP Paribas Arbitrage SA grew its holdings in shares of ANI Pharmaceuticals by 55,466.7% during the first quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $118,000 after buying an additional 1,664 shares during the last quarter. Hedge funds and other institutional investors own 64.22% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Further Reading: Market Capitalization – What it Means for Investors

Insider Buying and Selling by Quarter for ANI Pharmaceuticals (NASDAQ:ANIP)

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.